SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001731122-24-001812
Filing Date
2024-11-14
Accepted
2024-11-14 17:00:42
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q e6114_10q.htm   iXBRL 10-Q 1132946
2 EXHIBIT 31.1 e6114_ex31-1.htm EX-31.1 9263
3 EXHIBIT 31.2 e6114_ex31-2.htm EX-31.2 8376
4 EXHIBIT 32.1 e6114_ex32-1.htm EX-32.1 5463
5 EXHIBIT 32.2 e6114_ex32-2.htm EX-32.2 4379
  Complete submission text file 0001731122-24-001812.txt   4737170

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE vrpx-20240930.xsd EX-101.SCH 36691
7 XBRL CALCULATION FILE vrpx-20240930_cal.xml EX-101.CAL 37053
8 XBRL DEFINITION FILE vrpx-20240930_def.xml EX-101.DEF 145899
9 XBRL LABEL FILE vrpx-20240930_lab.xml EX-101.LAB 291621
10 XBRL PRESENTATION FILE vrpx-20240930_pre.xml EX-101.PRE 250151
61 EXTRACTED XBRL INSTANCE DOCUMENT e6114_10q_htm.xml XML 631852
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40064 | Film No.: 241463974
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)